Becca is an experienced FDA partner, regularly advising clients who develop, make, and distribute FDA-regulated products and who play a part in the investigation and delivery of health care products and services.
Becca has been advising life sciences companies on FDA and health care matters for over two decades, through changing administrations and policy agendas, the rapidly developing science and technology driving the industry, and both incremental and abrupt changes to the legal and regulatory landscape.
Experience
Representative matters
Representative matters
Advises clients in the medical technology space - including developers of a variety of apps and algorithms- on health care regulatory and compliance issues, in light of FDA's evolving approach to oversight of these technologies
Advises biopharma, device, and diagnostic companies on regulatory and contract issues raised by a variety of partnerships, collaborations and outsourcing relationships
Advises FDA-regulated companies, software vendors and service providers on the application of Part 11 electronic record requirements
Advises clients in the medical technology space - including developers of a variety of apps and algorithms- on health care regulatory and compliance issues, in light of FDA's evolving approach to oversight of these technologies
Advises biopharma, device, and diagnostic companies on regulatory and contract issues raised by a variety of partnerships, collaborations and outsourcing relationships
Advises FDA-regulated companies, software vendors and service providers on the application of Part 11 electronic record requirements
Reviews labeling, advertising, promotional materials and product claims for FDA-regulated products, including advising on specific applications of FDA’s “Consistent with FDA-required Labeling” guidance
Advises on communication strategies and social media campaigns, including considerations for the use of endorsements and testimonials -- by celebrities, influencers, healthcare professionals, and patients – relating to FDA-regulated products
Counsels on strategies for Medical Affairs communication efforts and related policies and procedures
Advises on interpretation of FDAMA 114 as amended by the 21st Century Cures Act, and FDA guidance on payor communications
Advises on FDA considerations for engagement with patients and disease advocacy organizations
Analyzes pharmaceutical, biologic, and medical device company policies, practices and documentation to assess areas of vulnerability under relevant regulatory standards and recommends methods to strengthen compliance efforts
Conducts internal investigations and assessments of regulated companies and entities in the areas of product promotion including FDA and fraud and abuse considerations
Supporting clients on numerous matters where radioactive materials are used in the life sciences industry, for example: obtaining supply of radioactive materials from outside the United States; compliance with NRC requirements in the context of brachytherapy devices; assessments and diligence relating to facilities permits for medical isotope production; and state licensure considerations in the import and supply chain for radiopharmaceuticals.
Prepares Quality Agreements for a wide range of pharmaceutical, biologic, and medical device and diagnostic companies and provides advice on Good Manufacturing Practices (GMP) compliance, vendor oversight and supply chain risk management
Advises on responses to 483 Inspectional Observations and Warning Letters
Advises on the federal Drug Supply Chain Security Act, and on state-level licensure and compliance requirements for manufacturers, distributors, pharmacies, and laboratories
Conducts internal investigations and assessments of regulated companies and entities in the areas of notifications and filings triggered by product changes, recall and corrections, manufacturing data integrity, and Good Manufacturing Practices
Develops strategy and provides advocacy and legal guidance for medical device manufacturers with innovative technologies throughout product development and the clearance/approval process
Provides guidance on Good Clinical Practice (GCP) issues arising in biopharma and medical device clinical trials
Advises on CLIA issues and Laboratory Developed Tests, and the interplay of CMS and FDA oversight of testing and diagnostics
Conducts internal investigations and assessments of regulated companies and entities in the areas of GCP and other study conduct and compensation matters
Recognitions
- Listed among Austin Monthly’s Top Attorneys for Health Care, 2025
- Shortlisted as Regulatory Attorney of the Year for FDA Medical Device by LMG Life Sciences Americas, 2025
- Selected as a finalist for Texas Lawyer’s Texas Legal Awards, Best Mentor, 2024
Credentials
Education
Education
- University of Texas School of Law, 2003, J.D., with honors
- Wake Forest University, 2000, B.A., Phi Beta Kappa
Professional admissions & qualifications
Professional admissions & qualifications
- Texas
- District of Columbia
- New York
Professional affiliations
Professional affiliations
- Food & Drug Law Institute (FDLI) – Austern Writing Awards Committee, 2022
- Advisory Council of Austin therapy-dog service provider Divine Canines – former member of the Board of Directors, including Chair Elect and Chair of the Board, 2011-2016
News
1 / 4
Insights
Blogs
1 / 5
Events
1 / 8